Medifast Stock Forecast, Price & News

Medifast (NYSE:MED) Frequently Asked Questions

Is Medifast a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view top-rated stocks.

How has Medifast's stock been impacted by Coronavirus (COVID-19)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 172.6% and is now trading at $192.03.
View which stocks have been most impacted by COVID-19.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Medifast.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) issued its quarterly earnings results on Thursday, November, 4th. The specialty retailer reported $3.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.92 by $0.64. The specialty retailer had revenue of $413.40 million for the quarter, compared to analysts' expectations of $402.80 million. Medifast had a net margin of 11.18% and a trailing twelve-month return on equity of 87.41%. Medifast's revenue was up 52.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.91 earnings per share.
View Medifast's earnings history.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, December 9th. Stockholders of record on Tuesday, December 21st will be paid a dividend of $1.42 per share on Tuesday, February 8th. This represents a $5.68 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Monday, December 20th.
View Medifast's dividend history.

Is Medifast a good dividend stock?

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 2.88%. Medifast has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Medifast is 42.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 35.08% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

What guidance has Medifast issued on next quarter's earnings?

Medifast updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of $13.270-$13.960 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $13.930. The company issued revenue guidance of $1.51 billion-$1.53 billion, compared to the consensus revenue estimate of $1.52 billion.

What price target have analysts set for MED?

3 equities research analysts have issued twelve-month price objectives for Medifast's shares. Their forecasts range from $265.00 to $400.00. On average, they anticipate Medifast's stock price to reach $338.00 in the next twelve months. This suggests a possible upside of 76.0% from the stock's current price.
View analysts' price targets for Medifast or view top-rated stocks among Wall Street analysts.

Who are Medifast's key executives?

Medifast's management team includes the following people:

• Daniel R. Chard, Executive Chairman & Chief Executive Officer
• James P. Maloney, Chief Financial Officer
• William Baker, Executive Vice President-Information Technology
• Jason L. Groves, Secretary, Executive VP & General Counsel
• Nicholas M. Johnson, EVP-Coach Success & Market President

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medifast's key competitors?

Some companies that are related to Medifast include Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.47%), Russell Investments Group Ltd. (0.26%), Chickasaw Capital Management LLC (0.25%), State of Alaska Department of Revenue (0.07%), Agate Pass Investment Management LLC (0.06%) and Louisiana State Employees Retirement System (0.05%). Company insiders that own Medifast stock include Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

Which major investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Crossmark Global Holdings Inc., Chickasaw Capital Management LLC, Nordea Investment Management AB, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, and Newbridge Financial Services Group Inc.. Company insiders that have sold Medifast company stock in the last year include Constance J Hallquist, Daniel R Chard, Kevin G Byrnes, and Scott Schlackman.
View insider buying and selling activity for Medifast or view top insider-selling stocks.

Which major investors are buying Medifast stock?

MED stock was purchased by a variety of institutional investors in the last quarter, including Agate Pass Investment Management LLC, First Hawaiian Bank, and Brookstone Capital Management.
View insider buying and selling activity for Medifast or or view top insider-buying stocks.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $192.03.

How much money does Medifast make?

Medifast has a market capitalization of $2.23 billion and generates $934.84 million in revenue each year. The specialty retailer earns $102.86 million in net income (profit) each year or $13.34 on an earnings per share basis.

How many employees does Medifast have?

Medifast employs 713 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

Where are Medifast's headquarters?

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at (410) 581-8042, via email at [email protected], or via fax at 410-581-8070.